News about "semaglutide "

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Semaglutide | 15/04/2026 | By News Bureau

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Semaglutide | 09/04/2026 | By News Bureau

NICE Recommends Weekly Semaglutide Injection to Prevent Heart Attacks and Strokes

NICE advises use of semaglutide injections for patients with prior cardiovascular conditions and excess weight to lower risk of future serious events.

Semaglutide | 04/04/2026 | By News Bureau

From Generics to Biologics: Semaglutide Reshapes Pharma Manufacturing in India

The recent developments around semaglutide in India—triggered by patent expiry and rapid domestic entry—are poised to significantly reshape the country’s pharmaceutical manufacturing landscape.

Semaglutide | 23/03/2026 | By Darshana |  134

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Semaglutide | 19/03/2026 | By News Bureau |  123

Samsung Bioepis and Epis NexLab Partner G2GBIO to Develop Long-Acting Semaglutide

Samsung Bioepis and Epis NexLab have signed a research collaboration and licensing agreement with G2GBIO to develop novel assets, including long-acting semaglutide, using G2GBIO’s proprietary microsphere drug delivery technology.

Semaglutide | 16/03/2026 | By News Bureau

UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk

UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.

Semaglutide | 07/02/2026 | By News Bureau |  487

UK MHRA Approves up to 7.2 mg Dose of Semaglutide for Obesity Treatment

The UK MHRA has approved a higher dose of semaglutide of up to 7.2 mg for weight management in adult patients with obesity. The regimen involves three 2.4 mg injections and is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with a Body Mass Index (BMI) of 30 kg/m² or higher.

Semaglutide | 17/01/2026 | By News Bureau |  122

Semaglutide Patent Expiry to Open Over USD 600 Million Opportunity for Generic Drugmakers

Industry estimates suggest that around 10 to 15 domestic and global drugmakers are likely to compete for this opportunity. In India, the introduction of generic semaglutide formulations, expected during the 2026–27 financial year, could generate incremental revenues of approximately USD 12–24 million within the branded formulations market.

Semaglutide | 06/01/2026 | By Darshana |  294

Novo Nordisk Secures Key China Patent Win for Semaglutide

The Supreme People’s Court of China has delivered a favourable ruling on the intellectual property rights related to the semaglutide compound patent, upholding an earlier decision by the Beijing Intellectual Property Court that confirmed the patent’s validity.

Semaglutide | 04/01/2026 | By Darshana |  313